When Yanay Ofran founded Biolojic Design in 2010, he had an ambitious vision: to create better, smarter drugs using computational biology, big data, and artificial intelligence.
Yanay’s new venture built on his research into biomolecular recognition — the process by which molecules recognize and bind to their molecular targets. In the university “garage lab,” Yanay began creating new tools to design amazing new molecules.
Within two years, the lab became a test kitchen for pharmaceutical companies seeking help with stalled projects.
Our team tackled these challenges and proved that they could program antibodies to carry out specific commands, unlocking a world of new capabilities.
As we grew, we saw the greater opportunity in front of us: to create our own pipeline of new programmable smart drugs. We recognized that existing therapeutics were only realizing a small fraction of antibodies’ potential. We set out to revolutionize the process for making smart drugs.